What is it about?
The review describes how the expansion or infusion of Treg cells treats autoimmune diseases and prevents Graft-versus-Host-Disease (GVHD) in experimental models and humans. In particular, the use of thymus-derived Treg (tTreg) cells, peripheral derived Treg (pTreg) cells, and CAR Treg cells is presented and critically evaluated. Technical problems and possible adverse events are discussed.
Featured Image
Why is it important?
One of the few reviews on the topic. A Table describing all the Treg-based treatments in humans is extremely up-to-date. The issue of Treg (tTreg, Th3, Tr1, and GITRsp) stability following infusion is discussed, and the use of polyclonal Treg cells, antigen-specific Treg cells, and CAR Treg cells is analyzed. Biologicals able to expand Treg cells are critically evaluated.
Perspectives
Read the Original
This page is a summary of: Treatment of Autoimmune Diseases and Prevention of Transplant Rejection and Graft-Versus-Host Disease by Regulatory T Cells: The State of the Art and Perspectives, January 2018, Elsevier,
DOI: 10.1016/b978-0-12-809912-4.00016-7.
You can read the full text:
Resources
Link to manuscript
The review (within a book) describes how the expansion or infusion of Treg cells treats autoimmune diseases and prevents Graft-versus-Host-Disease (GVHD) in experimental models and humans.
Researchgate
The review describes how the expansion or infusion of Treg cells treats autoimmune diseases and prevents Graft-versus-Host-Disease (GVHD) in experimental models and humans.
Contributors
The following have contributed to this page